相似文献
1
Towards New Broader Spectrum Pneumococcal Vaccines: The Future of Pneumococcal Disease Prevention.
Vaccines (Basel). 2014 Feb 14;2(1):112-28. doi: 10.3390/vaccines2010112.
2
Pneumococcal serotype evolution in Western Europe.
BMC Infect Dis. 2015 Oct 14;15:419. doi: 10.1186/s12879-015-1147-x.
3
Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.
Vaccine. 2013 Dec 16;31(52):6232-8. doi: 10.1016/j.vaccine.2013.10.032. Epub 2013 Oct 29.
4
Effectiveness of the seven-valent and thirteen-valent pneumococcal conjugate vaccines in England: The indirect cohort design, 2006-2018.
Vaccine. 2019 Jul 26;37(32):4491-4498. doi: 10.1016/j.vaccine.2019.06.071. Epub 2019 Jul 2.
5
Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized double-blind trial.
Clin Infect Dis. 2013 Oct;57(7):952-62. doi: 10.1093/cid/cit428. Epub 2013 Jun 26.
6
Effect of high-valency pneumococcal conjugate vaccines on invasive pneumococcal disease in children in SpIDnet countries: an observational multicentre study.
Lancet Respir Med. 2017 Aug;5(8):648-656. doi: 10.1016/S2213-2600(17)30110-8. Epub 2017 Mar 27.
7
Impact of pneumococcal conjugate vaccines on burden of invasive pneumococcal disease and serotype distribution of Streptococcus pneumoniae isolates: an overview from Kuwait.
Vaccine. 2012 Dec 31;30 Suppl 6:G37-40. doi: 10.1016/j.vaccine.2012.10.061.
8
Serotype coverage of invasive and mucosal pneumococcal disease in Israeli children younger than 3 years by various pneumococcal conjugate vaccines.
Pediatr Infect Dis J. 2009 Apr;28(4):277-82. doi: 10.1097/INF.0b013e31818e0e2e.
9
Dynamics of pneumococcal carriage among day-care center attendees during the transition from the 7-valent to the higher-valent pneumococcal conjugate vaccines in Greece.
Vaccine. 2014 Nov 12;32(48):6513-20. doi: 10.1016/j.vaccine.2014.09.016. Epub 2014 Sep 22.
10
Streptococcus pneumoniae serotype 19A: worldwide epidemiology.
Expert Rev Vaccines. 2017 Oct;16(10):1007-1027. doi: 10.1080/14760584.2017.1362339. Epub 2017 Aug 28.
引用本文的文献
1
Development of semisynthetic saponin immunostimulants.
Med Chem Res. 2024;33(8):1292-1306. doi: 10.1007/s00044-024-03227-x. Epub 2024 May 18.
2
Using LASSO Regression to Estimate the Population-Level Impact of Pneumococcal Conjugate Vaccines.
Am J Epidemiol. 2023 Jul 7;192(7):1166-1180. doi: 10.1093/aje/kwad061.
3
Potentiating pneumococcal glycoconjugate vaccine PCV13 with saponin adjuvant VSA-1.
Front Immunol. 2022 Dec 12;13:1079047. doi: 10.3389/fimmu.2022.1079047. eCollection 2022.
4
The 13-valent pneumococcal conjugate vaccine (PCV13) does not appear to provide much protection on combined invasive disease due to the six PCV13 non-PCV7 serotypes 1, 3, 5, 6A, 7F, and 19A in Kuwait during 2010-2019.
Hum Vaccin Immunother. 2021 Nov 2;17(11):4661-4666. doi: 10.1080/21645515.2021.1968216. Epub 2021 Aug 26.
5
Pneumococci Can Become Virulent by Acquiring a New Capsule From Oral Streptococci.
J Infect Dis. 2020 Jul 6;222(3):372-380. doi: 10.1093/infdis/jiz456.
6
Virulence and Host Immunity: Aging, Diagnostics, and Prevention.
Front Immunol. 2018 Jun 22;9:1366. doi: 10.3389/fimmu.2018.01366. eCollection 2018.
7
Morbidity and Mortality of a Cohort of Peruvian HIV-infected Children 2003-2012.
Pediatr Infect Dis J. 2018 Jun;37(6):564-569. doi: 10.1097/INF.0000000000001865.
8
Carrier priming to improve pneumococcal disease control and reduce the international program's cost in children.
Pneumonia (Nathan). 2016 Sep 27;8:16. doi: 10.1186/s41479-016-0016-8. eCollection 2016.
9
The Pneumococcal Serotype 15C Capsule Is Partially O-Acetylated and Allows for Limited Evasion of 23-Valent Pneumococcal Polysaccharide Vaccine-Elicited Anti-Serotype 15B Antibodies.
Clin Vaccine Immunol. 2017 Aug 4;24(8). doi: 10.1128/CVI.00099-17. Print 2017 Aug.
10
Self-assembled particulate PsaA as vaccine against infection.
Heliyon. 2017 Apr 11;3(4):e00291. doi: 10.1016/j.heliyon.2017.e00291. eCollection 2017 Apr.
本文引用的文献
1
The 7-valent pneumococcal conjugate vaccine elicits cross-functional opsonophagocytic killing responses to Streptococcus pneumoniae serotype 6D in children.
BMC Infect Dis. 2013 Oct 10;13:474. doi: 10.1186/1471-2334-13-474.
2
Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites.
PLoS Med. 2013;10(9):e1001517. doi: 10.1371/journal.pmed.1001517. Epub 2013 Sep 24.
3
Serotype 5 pneumococci causing invasive pneumococcal disease outbreaks in Barcelona, Spain (1997 to 2011).
J Clin Microbiol. 2013 Nov;51(11):3585-90. doi: 10.1128/JCM.01538-13. Epub 2013 Aug 21.
4
A Phase I, dose-escalation trial in adults of three recombinant attenuated Salmonella Typhi vaccine vectors producing Streptococcus pneumoniae surface protein antigen PspA.
Vaccine. 2013 Oct 1;31(42):4874-80. doi: 10.1016/j.vaccine.2013.07.049. Epub 2013 Aug 3.
5
Childhood invasive pneumococcal disease caused by non-7-valent pneumococcal vaccine (PCV7) serotypes under partial immunization in Taiwan.
J Formos Med Assoc. 2013 Sep;112(9):561-8. doi: 10.1016/j.jfma.2013.05.015. Epub 2013 Jul 31.
6
Streptococcus pneumoniae serotype 11D has a bispecific glycosyltransferase and expresses two different capsular polysaccharide repeating units.
J Biol Chem. 2013 Jul 26;288(30):21945-54. doi: 10.1074/jbc.M113.488528. Epub 2013 Jun 4.
7
Epidemiology of Streptococcus pneumoniae serogroup 6 isolates from IPD in children and adults in Germany.
PLoS One. 2013 Apr 9;8(4):e60848. doi: 10.1371/journal.pone.0060848. Print 2013.
8
Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine.
Pediatr Infect Dis J. 2013 Mar;32(3):203-7. doi: 10.1097/INF.0b013e318275614b.
9
Invasive pneumococcal disease after routine pneumococcal conjugate vaccination in children, England and Wales.
Emerg Infect Dis. 2013 Jan;19(1):61-8. doi: 10.3201/eid1901.120741.
10
Safety and immunogenicity of the pneumococcal pneumolysin derivative PlyD1 in a single-antigen protein vaccine candidate in adults.
Vaccine. 2013 Jan 2;31(2):327-33. doi: 10.1016/j.vaccine.2012.11.005. Epub 2012 Nov 12.
Zotero 插件